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Abstract: Currently available long-acting inhaled bronchodilators (tiotropium, salmeterol, 
formoterol) have demonstrated beneﬁ  cial effects on exacerbations in placebo-controlled trials. 
However, there have been no direct comparisons of these drugs with exacerbations as the primary 
outcome and consequently COPD treatment guidelines do not indicate a preference for either 
bronchodilator. Therefore, an international, randomized, double-blind, double-dummy, parallel-
group clinical trial has been designed to investigate the comparative efﬁ  cacy of 2 long-acting 
bronchodilators tiotropium 18 μg daily and salmeterol 50 μg bid on exacerbations. The trial 
will include at least 6800 randomized patients with diagnosis of COPD,  10 pack-year history 
of smoking, post-bronchodilator FEV1  70% predicted, and a history of exacerbations in the 
previous year. The primary endpoint is time to ﬁ  rst COPD exacerbation. Secondary endpoints 
include number of exacerbations and time to premature discontinuation of trial medication. 
The trial has been designed to address several of the challenges in studying exacerbations in a 
controlled trial by a symptom and event-based deﬁ  nition of exacerbations, frequent follow-up 
contacts, selection of time to ﬁ  rst event as the primary endpoint and using exposure adjusted 
analysis when examining number of events. Other challenges in designing exacerbation trials 
such as differential discontinuation and follow-up of discontinued patients are discussed.
Keywords: chronic obstructive pulmonary disease, exacerbation, salmeterol, study methodology, 
tiotropium
Introduction
Acute COPD exacerbations contribute considerably to the morbidity associated with 
COPD. Exacerbations result in signiﬁ  cant health care costs, disability, and are also 
responsible for premature death. Therefore, exacerbations are currently one of the 
most relevant outcome parameters in COPD trials. A differential effect of different 
drugs on exacerbations may affect the decision making of health care providers about 
ﬁ  rst-line maintenance treatment.1–3
Current guidelines recommend long-acting bronchodilators as ﬁ  rst line main-
tenance therapy for moderate, severe and very severe COPD, with a preference for 
inhaled medications over oral theophyllines.1,2 Presently, the once-daily anticholinergic 
tiotropium and the twice-daily beta 2-agonists salmeterol and formoterol are the most 
widely used maintenance medications with no speciﬁ  c guidance as to which agent is 
recommended as a ﬁ  rst choice. Both classes of agents have been demonstrated to be 
effective and hold favorable safety proﬁ  les.4–6
It has been shown that tiotropium and long-acting beta 2-agonists can have 
positive effects on the basic physiology of airﬂ  ow limitation and hyperinﬂ  ation as 
well as on patient-reported outcomes in patients with COPD.2 The evidence level has 
not generally shown clear distinctions between the two classes on more clinically 
oriented outcomes.International Journal of COPD 2009:4 120
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Direct comparisons between tiotropium and long-acting 
beta 2-agonists in patients with moderate to very severe 
COPD have generally been short term, with one published 
report of 2 combined studies being of 6 months duration in 
1207 patients.7 The studies of tiotropium compared with 
placebo and with salmeterol indicated superior bronchodilator 
efﬁ  cacy.7–11 However, these studies were not adequately 
powered to detect a difference in exacerbations. Nevertheless 
studies of 26 weeks’ duration may be considered as limited 
in terms of clinical conclusions. The evaluation of exacer-
bations should include an extended period of observation 
to minimize effects of seasonal variations. Studies of at 
least 1 year’s duration may therefore have advantages over 
shorter studies. Therefore, a 1-year study was designed to 
compare tiotropium to salmeterol with the primary outcome 
of exacerbations. The methodology involved in such a study 
raises challenging issues in study design that are discussed 
here. The purpose of this report is to describe the design of 
a recently initiated study in order to highlight issues related 
to study design for active comparator trials in COPD.
Methods
Study design
This is a 1-year international double-blind, double-dummy, 
randomized, parallel group trial to evaluate the effect of 
tiotropium 18 μg once-daily via the HandiHaler® compared 
to salmeterol hydroﬂ  ouroalkane (HFA) 50 μg bid via metered 
dose inhaler on exacerbations of COPD. The study involves 
a 2-week run-in period followed by a 1-year treatment phase. 
At run-in, patients on long-acting anticholinergic drug or a 
combination anticholinergic/beta-adrenergics are converted 
to a short-acting anticholinergic, which is discontinued at 
randomization to study drug. Patients taking long-acting 
beta 2-agonists continue their use during the run-in period. 
The run-in period with short-acting anticholinergics is 
necessary due to the prolonged terminal elimination half-
life of tiotropium (between 5 and 6 days). If this were not 
considered, prior tiotropium patients entering the salmeterol 
arm might contribute biased data due to a potential mixed 
effect of tiotropium and salmeterol. The short half-life of 
ipratropium used in the run-in period prevents the wash-
out concern with tiotropium. The long-acting beta agonist 
salmeterol can be administered just before randomization 
as its duration of action is only up to 12 hours, is rapidly 
eliminated with a plasma half-life of between 2 and 8 hours 
and is extensively metabolized.
DNA is being extracted from blood samples according 
to standard molecular methods and analyzed by standard 
genotyping technologies to examine possible effects of 
beta-adrenergic single nucleotide polymorphism on lung 
function in patients with COPD. Clinic visits are scheduled 
at 2, 4, 8 and 12 months. Monthly telephone contacts are 
scheduled between clinic visits (Figure 1). During the 
active study period, patients are allowed to take any COPD 
concomitant medication except long-acting beta 2-agonists 
(alone or in a ﬁ  xed combination with inhaled steroids) and 
anticholinergic drugs (alone or in a ﬁ  xed combination with 
short-acting beta 2-agonists). Spacer devices are not provided 
for salmeterol metered dose inhaler (MDI). All patients are 
offered salbutamol as rescue medication.
Patients prematurely withdrawn from study medication 
will be followed through telephone contact according 
to the clinic visit schedule for the one-year period from 
randomization to determine vital status. The ﬁ  rst patient 
was recruited in January 2008 and study results should be 
available in 2010. The study is conducted in accordance with 
the Declaration of Helsinki (1996) and Good Clinical Practice 
Guidelines.12 All patients must provide written informed 
consent before participating in the study. Ethics committees 
and authorities of all participating countries have approved 
this protocol. The trial is registered in clinicaltrials.gov under 
identiﬁ  er NCT00563381. The study ID number is 205.389.
Organizational committee
The study is being guided by a steering committee consisting 
of external clinical experts and representatives of Boehringer 
Ingelheim. The committee will remain blinded to data 
through the study period and is responsible for protocol 
amendments, analyses planning, data capture of health care 
resource use and cost data analysis, interpretation of data, 
and publication planning.
Study subjects
Criteria for participation include age 40 years or older, 
diagnosis of COPD, post-bronchodilator FEV1  70% of 
predicted normal and FEV1  70% of FVC and a smoking 
history of 10 pack years. Patients must have a history of 
at least 1 COPD exacerbation within the past year requiring 
treatment with antibiotics and/or systemic steroids and/or 
requiring hospitalization. Patients with signiﬁ  cant diseases 
other than COPD that would preclude participation in the 
trial or interpretation of the results are excluded. Patients 
with a current diagnosis of asthma, severe cardiovascular 
disorders and use of systemic corticosteroid medication 
at unstable doses are also excluded. Patients with any 
respiratory infection or COPD exacerbation in the 4 weeks International Journal of COPD 2009:4 121
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prior to the screening Visit (Visit 1) or during the run-in 
period are not permitted to participate. In the case of a 
respiratory infection or COPD exacerbation during the run-
in period, the latter may be extended up to 4 weeks to allow 
for randomization after the respiratory infection or COPD 
exacerbation is resolved.
Efﬁ  cacy, health- and economic outcomes
The primary endpoint is time to ﬁ  rst COPD exacerbation within 
1 year. Secondary endpoints include other exacerbation end-
points including hospitalizations due to COPD exacerbations 
(Table 1). A symptom and event based definition of 
exacerbation is being used in the trial. A COPD exacerbation is 
deﬁ  ned as a complex of respiratory events/symptoms (increase 
or new onset) of more than 1 of the following: cough, sputum, 
wheezing, dyspnoea or chest tightness with at least 1 symptom 
lasting at least 3 days requiring treatment with antibiotics 
and/or systemic steroids and/or hospitalization. The onset 
of an exacerbation is deﬁ  ned by the onset of the ﬁ  rst new or 
increased reported symptom. The end of the exacerbation will 
be based on the clinical assessment of the investigator.
Only moderate and severe exacerbations will be collected 
as they are considered clinically relevant. Moderate exacerba-
tions are deﬁ  ned as those requiring treatment with antibiotics 
and/or systemic steroids; those requiring hospitalizations 
are categorized as severe. Exacerbations based on the trial 
definition as well as healthcare resources used to treat 
these exacerbations will be collected via a questionnaire on 
regular clinic visits and telephone contacts. All patients are 
provided with a paper diary to serve as a reminder to support 
the structured questionnaire clinic and telephone interview. 
Use of medications and resource use associated with COPD 
exacerbations will be recorded within the trial in order to 
calculate direct health care costs and productivity losses by 
multiplying units with respective unit cost.
Vital status and exacerbations
For patients who prematurely discontinue study medication, 
vital status along with the primary cause of death will be 
recorded. The information will be gathered via phone at the 
scheduled clinic visits starting 4 months after randomization 
until the end of the trial. In case of a patient’s death, 
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Figure 1 Study design.
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information will be collected based on information of the 
treating physicians, death certiﬁ  cates, autopsy or other medical 
documentation. Exacerbations following treatment discontinu-
ation will not be collected unless the exacerbation was fatal.
Statistical analysis
The primary and all secondary time-to-event endpoints will be 
analyzed using Cox proportional hazards regression stratiﬁ  ed by 
center. Cochrane Mantel Haenszel (CMH) test will be used for 
risk ratios, Poisson regression with correction for exposure and 
over dispersion will be used to analyse event rates. For safety, 
serious adverse events and mortality will be analyzed.
A review of tiotropium studies (both placebo and active 
controlled studies)7–11,13–17 in patients with COPD was 
performed to estimate the risk of at least 1 exacerbation 
within 52 weeks of treatment with tiotropium and the 
risk reduction compared with salmeterol. Studies applied 
similar inclusion and exclusion criteria and collected similar 
information on COPD exacerbations. The planned sample 
size has been calculated to be 6800 patients (3400 per 
treatment group), assuming a 40% risk to experiencing at 
least one COPD exacerbation within one year for tiotropium 
and a constant hazard ratio of 0.90. The study has 80% power 
to reject the null hypothesis of equal hazards (no difference 
between tiotropium and salmeterol) at the 5% level of 
signiﬁ  cance. A protocol deﬁ  ned blinded interim analysis 
to assess event rates will be used to determine whether the 
sample size may need to be adjusted.
Discussion
COPD exacerbations have a negative impact on health-related 
quality of life,18 may promote disease progression19,20 and are 
a common cause of hospitalization and mortality.21 Therefore, 
reducing the occurrence of exacerbations continues to be 
an important goal of COPD treatment. Different classes of 
respiratory medications have been shown to accomplish this 
goal by either reducing the absolute frequency or the severity 
of exacerbations.10,22
While lung function differences can be observed in 
clinical trials of active compounds,7,8 trials comparing active 
compounds designed to evaluate COPD exacerbations as a 
primary outcome are uncommon. A study by Kardos et al23 
demonstrated that combination therapy with salmeterol/
fluticasone compared with salmeterol monotherapy 
significantly reduced the frequency of moderate/severe 
exacerbations in patients with severe COPD and a 
history of repeated exacerbations. More recently, the 
INSPIRE study compared the long-term effect of a ﬁ  xed 
salmeterol/ﬂ  uticasone combination versus tiotropium on 
COPD exacerbations, demonstrating a similar reduction in 
Table 1 Efﬁ  cacy and safety endpoints
Primary efﬁ  cacy endpoint
 Time  to  ﬁ  rst COPD exacerbation
Secondary efﬁ  cacy endpoints
  Occurrence of at least one exacerbation
  Number of COPD exacerbations
 Time  to  ﬁ  rst hospitalization due to COPD exacerbation
  Occurrence of at least one hospitalization due to COPD exacerbations
  Number of hospitalizations due to COPD exacerbations
  Time to premature discontinuation of trial medication
  Occurrence of premature discontinuation of trial medication
  Pre-dose morning PEFR measured by patients at home during the ﬁ  rst 4 months of randomized treatment (weekly means will be calculated)
 Time  to  ﬁ  rst COPD exacerbation or time to discontinuation of study medication because of worsening of underlying disease, whichever comes ﬁ  rst
Safety endpoints
  Serious adverse events
  Adverse events leading to treatment discontinuation
  All-cause mortality during treatment with study medication
  All-cause mortality including follow-up of vital status from patients who prematurely discontinue treatment
 Physical  examination
Other secondary endpoints
  Health care utilization and absence from paid work
Abbreviation: PEFR, peak expiratory ﬂ  ow rate.International Journal of COPD 2009:4 123
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exacerbations for both active drugs.24 Nevertheless, there 
is sparse evidence on the comparative effect of different 
long-acting bronchodilators on COPD exacerbations. Con-
sequently, contemporary guidelines do not give preference 
to either bronchodilator.
The study is designed to investigate the comparative 
efﬁ  cacy of 2 long-acting bronchodilators with different 
modes and durations of action, ie, the once-daily long-
acting anticholinergic tiotropium versus the twice-daily 
long-acting beta 2-agonist salmeterol. The study will be 
sufﬁ  ciently powered to demonstrate the superiority of one 
of the drugs in respect of the primary endpoint, time to ﬁ  rst 
COPD exacerbation. The study will involve at least 6800 
randomized patients from approximately 900 study centers 
in 26 countries. COPD patients in the study will be treated 
for 1 year in order to reduce potential biases that may result 
from seasonal variation.
Long-term clinical trials in COPD are faced with several 
methodological challenges. Critical to the outcome is a precise 
and feasible deﬁ  nition of an exacerbation. The trial employs 
a symptom- and event-based deﬁ  nition of exacerbations, 
combining the COPD exacerbation deﬁ  nitions as proposed 
by Rodriguez-Roisin25 and Casaburi13 and recently endorsed 
by an ATS/ERS (American Thoracic Society/European 
Respiratory Society) Task Force.3 The trial focuses on 
moderate (requiring treatment with antibiotics and/or systemic 
steroids) and severe (requiring hospitalization) exacerbations, 
because the clinical relevance of mild exacerbations is 
unclear. Thus, it may be argued that the deﬁ  nition in the 
present trial bears the potential for underestimating exac-
erbations; however, distinguishing variations in day to day 
symptoms from a “mild” exacerbation is difﬁ  cult. In addition, 
mild exacerbations may be dealt without any contact with 
the physician. Thus, the data collected would primarily rely 
on the patients´ interpretation of their well-being. Therefore, 
it is preferable to use an event-based deﬁ  nition that requires 
a decision by the physician to prescribe treatment with 
systemic steroids and/or antibiotics. The disadvantage of 
using an event-based deﬁ  nition of exacerbation severity is 
that deﬁ  nitions are sensitive to variations between countries 
and settings in medical practice with respect to prescribing 
antibiotics/systemic steroids and hospitalizations.
One consideration in developing deﬁ  nitions is using 
a blinded adjudication process (ie, a clinical endpoints 
committee) in order to achieve a standardized and objective 
classiﬁ  cation of an endpoint.26 This approach is considered 
appropriate in determining the primary cause of death in 
a clinical trial.27 However, in this study there is no need 
to adjudicate the primary endpoint given the exacerbation 
criteria. Exacerbation information is collected via a pre-
deﬁ  ned questionnaire and will have to meet the trial deﬁ  nition 
of an exacerbation.
Other issues in outcome trials include withdrawal of 
baseline medications and how to address non-random premature 
discontinuations.28 Recently, concerns have been raised as to 
whether withdrawal of therapies at entry to study may lead to a 
bias.26,29,30 This likely will have a minimal impact on the current 
study as patients will be treated with effective accepted main-
tenance treatment in both intervention groups and can continue 
other maintenance therapies including inhaled corticosteroids 
and theophyllines. However, sensitivity analyses will be 
performed to investigate whether maintenance therapy prior to 
study start has an impact on the results. Non-random premature 
discontinuation of patients may also introduce a bias, which 
argues in favor of collecting follow-up data. However, other 
factors should be considered. The majority of patients stopping 
blinded treatment with tiotropium or salmeterol are likely 
to be treated subsequently with tiotropium or salmeterol or 
both. Therefore, inclusion of data from discontinued patients 
will lead to a dilution of the effect or signiﬁ  cant difﬁ  culties 
in attributing an effect to one drug when the patient actually 
may be receiving the other drug (as prescribed openly by their 
physician). Furthermore, there is also a high risk of lower 
quality data (ie, it is unlikely that reporting of exacerbations 
will be as reliable as prior to discontinuation). Due to these 
reasons, data on exacerbations following drug discontinuation 
will not be collected in this trial.
The time to ﬁ  rst COPD exacerbation was selected as 
the primary endpoint. This choice was made as time to ﬁ  rst 
exacerbation is considered to be the most robust parameter 
for assessing COPD exacerbations in clinical trials. It is 
readily understood, the statistical theory for analysis is 
well established and resulting estimators are generally 
unbiased. A recent publication outlined the complexities and 
challenges in examining other exacerbation endpoints such 
as number of events, which further supports the decision 
for the primary endpoint in the present trial.26 Time to ﬁ  rst 
COPD exacerbation avoids major disadvantages of other 
exacerbation endpoints (ie, the number of exacerbations) 
such as: (a) separation of exacerbation events from events 
that are close in time, (b) change in maintenance therapy 
subsequent to events which may result in underestimation of 
exacerbation rates and uneven distribution across treatment 
groups, and (c) the effects of early discontinuation due 
to an event. Withdrawal prior to the ﬁ  rst event that is not 
completely at random also affects estimates of time to ﬁ  rst International Journal of COPD 2009:4 124
Beeh et al
exacerbation. With regard to discontinuation, statistical 
methods such as Poisson regression adjust for exposure time. 
However, this method presumes that exacerbations observed 
in a patient are independent events (ie, no change in main-
tenance therapy due to a previous event). A disadvantage of 
the endpoint “time to ﬁ  rst exacerbation” may be that the data 
are more difﬁ  cult to interpret by clinicians.
The investigation of the comparative efﬁ  cacy of two 
long-acting bronchodilators is the main focus of this study, 
but the lack of resources available to satisfy the continuously 
increasing demand for health care has led to an increased 
interest in costs and health-economic outcomes. Therefore 
a cost-effectiveness study will be conducted that includes all 
COPD-related medication costs as well as all exacerbation-
related costs of healthcare utilization and absence from paid 
work. The direct COPD-related health care costs also include 
the downstream costs of the pharmacotherapies that are evalu-
ated, ie, hospitalizations, emergency room visits, unscheduled 
care-giver visits, ambulance transportation and medications 
such as the increased use of bronchodilators, antibiotics 
and oral corticosteroids. Only COPD-related costs will be 
included and not total costs because this allows greater preci-
sion in detecting the effects of the treatments by minimizing 
the “noise” that occurs when all costs are included.
In conclusion, the trial represents a unique opportunity 
to study the differences between two well established long-
acting bronchodilators in COPD patients with a history of 
moderate and severe exacerbations. The knowledge gained 
from the study may help physicians to guide their treatment 
decision and is also going to inﬂ  uence future national and 
international COPD guidelines.
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